Critisense

Company Overview

Snapshot

Founded in January 2004, Critisense operates with 1–10 employees. The company is currently in a Pre-Funding stage.

Business overview

Critisense develops technology for real-time monitoring of patients' metabolic state, serving as an endpoint of resuscitation. Its primary product, CritiView, is a patient-monitoring system that provides continuous information via four physiological parameters, sensed at the tissue level to reflect systemic metabolic state. CritiView monitors mitochondrial function and microcirculatory blood flow and oxygen saturation, offering early identification and warning of critical metabolic imbalances or issues with tissue viability. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices, Diagnostics Devices, and Medical Monitors, targeting healthcare providers.

Company Intelligence Q&A

What is Critisense's primary product?

Critisense's first-generation product, CritiView, is a patient-monitoring system that provides real-time continuous information on physiological parameters at the tissue level.

What does CritiView monitor?

CritiView monitors mitochondrial function, microcirculatory blood flow, and oxygen saturation to provide continuous, real-time, multi-parametric physiological data at the tissue and cellular level.

What is the primary benefit of CritiView?

CritiView provides early identification and warning of critical metabolic imbalances or tissue viability issues, allowing clinicians to make more refined corrective medical actions earlier than current critical-care monitors.

In which sector does Critisense primarily operate?

Critisense operates within the Health Tech & Life Sciences sector, focusing on Medical Devices, Diagnostics Devices, and Medical Monitors.

What is the current status of Critisense?

Critisense is currently in a Non Active status as of November 2016 and is in a Pre-Funding stage.